+++ US-BIOTECHWERT vor KURSEXPLOSION! +++
Seite 1 von 1 Neuester Beitrag: 14.10.03 16:13 | ||||
Eröffnet am: | 05.03.03 12:45 | von: BörsenStar2. | Anzahl Beiträge: | 7 |
Neuester Beitrag: | 14.10.03 16:13 | von: bilal61191 | Leser gesamt: | 1.979 |
Forum: | Hot-Stocks | Leser heute: | 0 | |
Bewertet mit: | ||||
LAM PHARMACEUTCALS WKN 631629
Neues Produkt in Pipeline!!!
Charttechnisch Kaufsignal generiert: Bereits 3x in Folge leicht im Plus könnte Ausbruch bis zur Widerstandslinie bei ca. 50-60 $-cents kurz bevorstehen!
So sieht das auch der folgende Newsletter:
L.A.M. PHARMACEUTICAL CP
0.275
+0.015 +5.77%
Daily Commentary
BUY
Our system recommends BUY as of today. Previous SELL recommendation was made on 2/26/2003 (6) days ago, when the stock
price was 0.230. Since then the stock gained 19.57% .
Today the stock closed higher, at its high (sign of strength) with a higher high and a higher low. The volume is normal. The security price
is trending up.
There is a strong upward move that turned up all the moving averages. This may be a sign of a new uptrend. It is still not too late to buy
this stock.
Candlestick Analysis
Today’s Candlestick Patterns:
White Marubozu
Today a White Marubozu formed. Buyers have controlled the price action from the first trade to the last trade. Be careful, this may lead to
excessive bullishness!
Stock Quote
Last 0.275
Previous Close 0.260
Change +0.015
% Change +5.77%
Volume 113,800
Stock Activity
Open 0.245
Day`s High 0.275
Day`s Low 0.245
52 Week High 2.050
52 Week Low 0.190
Stock Price History
3 Month % Change -14.06
6 Month % Change -53.39
12 Month % Change -60.71
Stock Statistics
50 Day Close MA 0.262
200 Day Close MA 0.516
65 Day Volume MA 125,643
Aktuell: Klarer Kauf - auch in Deutschland handelbar!
Börsenstar
Neues Produkt in Pipeline!!!
Charttechnisch Kaufsignal generiert: Bereits 3x in Folge leicht im Plus könnte Ausbruch bis zur Widerstandslinie bei ca. 50-60 $-cents kurz bevorstehen!
So sieht das auch der folgende Newsletter:
L.A.M. PHARMACEUTICAL CP
0.275
+0.015 +5.77%
Daily Commentary
BUY
Our system recommends BUY as of today. Previous SELL recommendation was made on 2/26/2003 (6) days ago, when the stock
price was 0.230. Since then the stock gained 19.57% .
Today the stock closed higher, at its high (sign of strength) with a higher high and a higher low. The volume is normal. The security price
is trending up.
There is a strong upward move that turned up all the moving averages. This may be a sign of a new uptrend. It is still not too late to buy
this stock.
Candlestick Analysis
Today’s Candlestick Patterns:
White Marubozu
Today a White Marubozu formed. Buyers have controlled the price action from the first trade to the last trade. Be careful, this may lead to
excessive bullishness!
Stock Quote
Last 0.275
Previous Close 0.260
Change +0.015
% Change +5.77%
Volume 113,800
Stock Activity
Open 0.245
Day`s High 0.275
Day`s Low 0.245
52 Week High 2.050
52 Week Low 0.190
Stock Price History
3 Month % Change -14.06
6 Month % Change -53.39
12 Month % Change -60.71
Stock Statistics
50 Day Close MA 0.262
200 Day Close MA 0.516
65 Day Volume MA 125,643
Aktuell: Klarer Kauf - auch in Deutschland handelbar!
Börsenstar
LAM PHARMA akt. 29 $-cents---noch immer ein KAUF!!!
Hier könnte es jetzt sehr schnell gehen, neues Medikament, verbesserte Marketingstrategie...
KZ 50 $-cents!
Brsenstar
Hier könnte es jetzt sehr schnell gehen, neues Medikament, verbesserte Marketingstrategie...
KZ 50 $-cents!
Brsenstar
LAM PHARMA WKN 631629
Konsolidierung zum Einstieg nutzen!
Unter 30 cents klarer Kaufkurs!!!
Aktuelle Spanne 26-28 cents...
KZ 50 cents.
Börsenstar
Konsolidierung zum Einstieg nutzen!
Unter 30 cents klarer Kaufkurs!!!
Aktuelle Spanne 26-28 cents...
KZ 50 cents.
Börsenstar
Hast du dir heute die 11.500 Stück in Berlin gekauft?
|
|
Damit wurde heute fast schon doppelt soviel umgesetzt, wie das 52W-Durchschnittsvolumen, wenn das mal kein gutes Omen ist!!!
Gruß
masteruz
ist lamp die zweite callybte???????????????
LAM Pharmaceutical Completes Equity Financing and Strengthens Balance Sheet
Tuesday October 14, 7:03 am ET
LEWISTON, N.Y., Oct. 14 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today the successful completion of an equity financing. The financing was comprised of cash subscriptions for shares and warrants by third party investors. In addition, five persons, including LAM`s officers and directors, subscribed for shares and warrants in payment of past money owed to these persons by LAM. Collectively, LAM`s net asset position was improved by approximately $958,000.
" Our ability to complete this equity capital placement reflects growing confidence in management`s plan to expand the Company`s revenue base for its LAM IPM Wound Gel(TM) through licensing and strategic partnerships, and to broaden its product base through acquisition of compatible product lines," noted Joseph Slechta, President and Chief Executive Officer of LAM. " LAM`s long term vision is to become a diversified healthcare company with international scope, focused on the development, licensing and distribution of novel proprietary and third party health care products. We will continue working with our current capital sources and seek new sources of long term capital to support our growth initiatives."
Mr. Slechta concluded, " I am delighted to see that the officers and directors of the Company have shown their total support for the growth prospects by participating in this financing in such a substantial way."
About LAM Pharmaceutical, Corp.
L.A.M. Pharmaceutical, Corp., www.lampharm.com, is a biomedical company with laboratories
LAM Pharmaceutical Completes Equity Financing and Strengthens Balance Sheet
Tuesday October 14, 7:03 am ET
LEWISTON, N.Y., Oct. 14 /PRNewswire-FirstCall/ -- LAM Pharmaceutical, Corp. (OTC Bulletin Board: LAMP; Frankfurt: LAM; Berlin: LAM), a biomedical company focused on the development and commercialization of novel wound healing and transdermal drug delivery systems, announced today the successful completion of an equity financing. The financing was comprised of cash subscriptions for shares and warrants by third party investors. In addition, five persons, including LAM`s officers and directors, subscribed for shares and warrants in payment of past money owed to these persons by LAM. Collectively, LAM`s net asset position was improved by approximately $958,000.
" Our ability to complete this equity capital placement reflects growing confidence in management`s plan to expand the Company`s revenue base for its LAM IPM Wound Gel(TM) through licensing and strategic partnerships, and to broaden its product base through acquisition of compatible product lines," noted Joseph Slechta, President and Chief Executive Officer of LAM. " LAM`s long term vision is to become a diversified healthcare company with international scope, focused on the development, licensing and distribution of novel proprietary and third party health care products. We will continue working with our current capital sources and seek new sources of long term capital to support our growth initiatives."
Mr. Slechta concluded, " I am delighted to see that the officers and directors of the Company have shown their total support for the growth prospects by participating in this financing in such a substantial way."
About LAM Pharmaceutical, Corp.
L.A.M. Pharmaceutical, Corp., www.lampharm.com, is a biomedical company with laboratories